Cumberland Pharmaceuticals Non-GAAP EPS of $0.16, revenue of $11.7M

Stock Information for Cumberland Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.